Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial

Journal of the National Cancer Institute

Volumn 102, Issue 18, 2010, Pages 1413-1421

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b   Manson, Joann E ^c   Schwartz, Ann G ^d   Wakelee, Heather ^e   Gass, Margery ^f   Rodabough, Rebecca J ^b   Johnson, Karen C ^g   Wactawski Wende, Jean ^h   Kotchen, Jane Morley ⁱ   Ockene, Judith K ^j   O'Sullivan, Mary Jo ^k   Hubbell, F Allan ^l   Chien, Jason W ^b   Chen, Chu ^b   Stefanick, Marcia L ^e  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF MIAMI   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO; GESTAGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOMEN'S HEALTH; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHEMICALLY INDUCED; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; UNITED STATES;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; UNITED STATES; WOMEN'S HEALTH;

EID: 77957257347     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq285     Document Type: Article

References (50)

1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
2. Chlebowski RT, Schwartz AG, Wakelee H, et al. Estrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial. Lancet. 2009; 374(9697):1243-1251.
3. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss on lung cancer management. Nutrition. 1996; 12(suppl 1):S42-S47.
4. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1(5):441-446
5. International Early Lung Cancer Action Program Investigators. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296(2):180-184.
6. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. 1990;50(20):6632-6635.
7. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62(7):2141-2150.
8. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 2007;25(36):5785-5792.
9. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 1994;86(11):869-870.
10. Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer. 2005; 117(4):662-666.
11. Kruezer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol. 2003;32(2):263-271.
12. Elliott AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception. 2006;73(4):331-335
13. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
14. Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol. 2003;102(3):565-570.
15. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res. 2004;10(1 pt 1):113-123.
16. Ramnath N, Menezes RJ, Loewen G, et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology. 2007;73(5-6):305-310.
17. Rodriguez C, Spencer Feigelson H, Deka A, et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(3): 655-660.
18. Chlebowski RT. Menopause hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol. 2009;36(6):566-571.
19. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;(suppl 9):S5-S17.
20. National Cancer Institute. Surveillance, epidemiology and end results. 2006. http://seer.cancer.gov/. Accessed July 22, 2009.
21. Curb D, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(suppl 9):S122-S128.
22. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
23. Cox DR. Regression analysis and life tables. JR Stat Soc. 1972;34(2): 187-220.
24. Chlebowski RT, Hendrix SL, Langer RD, et al. Infuence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003; 289(24):3243-3253.
25. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
27. Chlebowski RT, Kuller L, Prentice RL, et al. Breast cancer after estrogen plus progestin use in postmenopausal women. N Engl J Med. 2009;360(6): 573-587.
28. Stefanick M, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Trial. JAMA. 2006;295(14):1647-1657.
29. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17(10): 2609-2618.
30. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA. 2003;290(13):1739-1748
31. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;275(5):370-375
32. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470): 1543-1551.
33. Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1724-1731.
34. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89(15):1110-1116.
35. Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the nurses' health study cohort 1976-2004. Int J Cancer. 2010; 126(1):208-216.
36. Wu CY, Change YL, Shih JY, Lee YC. The signifcance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg. 2005;130(4):979-986.
37. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 2005; 11(14):5084-5089.
38. Skov BG, Fischer BM, Pappot H. Estrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer. 2008;59(1):88-94.
39. Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27(3):411-417.
40. Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in non-small cell lung cancer\a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 2005;65(14):6450-6458. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
41. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
42. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
43. Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defned mouse model of lung adenocarcinoma. Endocr Relat Cancer. 2008;15(2):475-483, The Coronary Drug Project Research Group
44. The Coronary Drug Project Research Group. The Coronary Drug Project: fndings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA. 1973;226(6):652-657.
45. Greiser EM, Doser M. Menopausal hormone therapy and risk of lung cancer\systematic review and meta-analysis. Maturitas. 2010;65(3): 198-204.
46. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the Vitamins and Lifestyle Study. J Clin Oncol. 2010;28(9):1-7.
47. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006;24(1):59-63.
48. Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer. 2009;115(18):4167-4175.
49. Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small cell lung cancer: can an association be confrmed? Curr Oncol. 2009;16(3):21-25.
50. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87(1):6-12.